Brii Biosciences, Vir Biotechnology, Inc., and VBI Vaccines Inc. announced that the first patient had been dosed in a Phase II clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid targeting hepatitis B virus, in combination with BRII-179, an investigational HBV immunotherapeutic, for the treatment of chronic HBV infection.
[Brii Biosciences, Vir Biotechnology, Inc., and VBI Vaccines, Inc. (GLOBENEWS WIRE)]
7753456 nan items 1 apa default asc 1
Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of chronic hepatitis B patients in the ongoing ALG-000184-201 study.
[Aligos Therapeutics, Inc. (GLOBENEWS WIRE)]
7753456 nan items 1 apa default asc 1
Scientists hypothesized that the pace of fibrosis progression might reflect changes in gene expression within the aging liver.
[Proceedings of the National Academy of Sciences of the United States of America]
7753456 NST8CZUH items 1 apa default asc 1
Nishimura, N., Battista, D. D., McGivern, D. R., Engle, R. E., Tice, A., Fares-Gusmao, R., Kabat, J., Pomerenke, A., Nguyen, H., Sato, S., Bock, K. W., Moore, I. N., Kleiner, D. E., Zamboni, F., Alter, H. J., Govindarajan, S., & Farci, P. (2021). Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proceedings of the National Academy of Sciences, 118(17). https://doi.org/10.1073/pnas.2019633118 Cite
Researchers investigated the detailed biological role of muskelin 1 antisense RNA (MKLN1)-AS and Yes-associated transcriptional regulator 1 (YAP1)-related mechanisms.
[Experimental and Molecular Pathology]
7753456 33C4AA7U items 1 apa default asc 1
we summarize the microRNAs and transcription factors that regulate the autophagy pathway in nonalcoholic fatty liver disease.
[Experimental and Molecular Medicine]
7753456 MB47TMXC items 1 apa default asc 1
VBI Vaccines. Inc., announced data and next steps from the high-dose cohort of its Phase Ib/IIa clinical study of VBI-2601 (BRII-179), the company’s hepatitis B immunotherapeutic candidate, in chronically-infected hepatitis B patients.
[VBI Vaccines, Inc. (businesswire)]
6445212 nan items 1 apa default asc 1
VBI Vaccines Inc. announced data and next steps from the high-dose cohort of its Phase Ib/IIa clinical study of VBI-2601, the company’s hepatitis B immunotherapeutic candidate, in chronically-infected hepatitis B patients.
[VBI Vaccines Inc. (BusinessWire, Inc)]
6445218 nan items 1 apa default asc 1
Scientists discuss how the immune responses to dysbiotic microbiota that cross the damaged barrier may be involved in the development of allergic and autoimmune diseases.
[Nature Reviews Immunology]
Scientists investigated the protective mechanism of CBLB502 in the liver using models of ischemia-reperfusion injury and concanavalin A induced immuno-hepatitis.
[Cell Death & Disease]
6445212 YFL88S95 items 1 apa default asc 1
Scientists found that patients with early natural killer cell activation after PEG–IFN-α injection experienced greater liver inflammation, lysis of HBV-infected hepatocytes, and hepatitis B surface antigen decline than those without.
[Science Translational Medicine]
6445218 98V83KPK items 1 apa default asc 1
Nishio, A., Bolte, F. J., Takeda, K., Park, N., Yu, Z.-X., Park, H., Valdez, K., Ghany, M. G., & Rehermann, B. (2021). Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. Science Translational Medicine, 13(587). https://doi.org/10.1126/scitranslmed.aba6322 Cite
Tumor necrosis factor‐α‐induced protein 8‐like 2 suppressed nonalcoholic fatty liver disease (NAFLD) advancement by blocking transforming growth factor‐beta‐activated kinase 1‐c‐Jun NH2‐terminal kinase/p38 pathway and was a promising target molecule for NAFLD therapy.
6606345 SNSIFRRC items 1 apa default asc 1